Roger Montgomery's Team
articles by Roger Montgomery's Team
-
-
-
-
-
SIRTEX UPDATE
Roger Montgomery's Team
March 17, 2015
Executive Summary
At 28 February 2015, Sirtex (ASX: SRX) represented a circa 6.5 per cent position across Montgomery Funds. After close analysis of Roche’s Kadcyla life cycle – something we reported to The Montgomery [Private] Fund investors in their February 2015 Performance Report – the Montgomery Investment Committee took steps to protect investor capital. In the first two weeks of March 2015, Montgomery cut its investors’ exposure to Sirtex by approximately 35 per cent at an average price of $35.50. After detailed analysis and discussion with various experts, Montgomery re-entered the market today repurchasing those shares it sold at less than half the price at which they were sold. Continue…
by Roger Montgomery's Team Posted in Health Care.
- 45 Comments
- save this article
- 45
- POSTED IN Health Care.
-
-
-
-
-
